Information about Mepenzolate
Mepenzolate is an anticholinergic agent used to treat gastrointestinal conditions such as acid peptic disease and irritable bowel syndrome.
Liver safety of Mepenzolate
Mepenzolate has not been implicated in causing liver enzyme elevations or clinically apparent acute liver injury.
Mechanism of action of Mepenzolate
Mepenzolate (me pen' zoe late) is a synthetic quaternary ammonium anticholinergic agent which inhibits the muscarinic actions of acetylcholine on autonomic nerve endings, decreasing gastrointestinal secretions and intestinal motility. Mepenzolate has broad activity against muscarinic acetylcholine receptors, but its highly polar quaternary ammonium group makes it less likely to cross lipid membranes such as the blood brain barrier, which is believed to decrease the potential for central nervous system effects. Mepenzolate has been used largely for gastrointestinal conditions including peptic ulcer disease and gastrointestinal conditions associated with pain and spasm.
FDA approval information for Mepenzolate
Mepenzolate is approved for use in the United States for the treatment of peptic ulcer disease but is now not commonly used, having been replaced by more effective antiulcer agents. Mepenzolate is available in tablets 25 mg under the brand name Cantil.
Dosage and administration for Mepenzolate
The typically recommended oral dose in adults is 25 to 50 mg two to four times daily.
Side effects of Mepenzolate
Common side effects are those of parasympathetic stimulation and include dryness of the mouth and eyes, decreased sweating, headache, visual blurring, constipation, and urinary retention. Because of its structure, mepenzolate is believed to be less likely than other anticholinergics to cross the blood brain barrier and cause central nervous system effects such as restlessness, confusion and hallucinations. Anticholinergic agents can precipitate acute narrow angle glaucoma and acute urinary retention.